Tilomisole
Tilomisole (WY-18,251) is an experimental drug which acts as an immunomodulator and has been studied for the treatment of some forms of cancer.[1][2]
References
- ↑ Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology 2 (4): 491–508. PMID 6970786.
- ↑ Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy 4 (1): 10–4. PMID 1385709.
|
---|
| Intracellular (initiation) | |
---|
| Intracellular (reception) | |
---|
| Extracellular | |
---|
|